Добірка наукової літератури з теми "Clozapine"

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Clozapine".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Clozapine"

1

Pardis, Parnian, Gary Remington, Roshni Panda, Milan Lemez, and Ofer Agid. "Clozapine and tardive dyskinesia in patients with schizophrenia: A systematic review." Journal of Psychopharmacology 33, no. 10 (2019): 1187–98. http://dx.doi.org/10.1177/0269881119862535.

Повний текст джерела
Анотація:
Background: It is commonly recommended that a switch to clozapine be implemented in the face of tardive dyskinesia, even if current treatment involves another “atypical” agent. However, reports do indicate clozapine carries a liability for tardive dyskinesia. Aims: This review sought to evaluate clozapine in relation to tardive dyskinesia in the context of available evidence. Methods: Medline, Embase, and PsycINFO databases were searched for studies published in English, using the keywords: clozapine AND tardive dyskinesia OR TD. References from major review articles were searched for addition
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Qubad, Mishal, and Robert A. Bittner. "Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia." Therapeutic Advances in Psychopharmacology 13 (January 2023): 204512532311581. http://dx.doi.org/10.1177/20451253231158152.

Повний текст джерела
Анотація:
Despite its enduring relevance as the single most effective and important evidence-based treatment for schizophrenia, underutilization of clozapine remains considerable. To a substantial degree, this is attributable to a reluctance of psychiatrists to offer clozapine due to its relatively large side-effect burden and the complexity of its use. This underscores the necessity for continued education regarding both the vital nature and the intricacies of clozapine treatment. This narrative review summarizes all clinically relevant areas of evidence, which support clozapine’s wide-ranging superior
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Rajkumar, Anto P., B. Poonkuzhali, Anju Kuruvilla, Alok Srivastava, Molly Jacob, and K. S. Jacob. "Association betweenCYP1A2gene single nucleotide polymorphisms and clinical responses to clozapine in patients with treatment-resistant schizophrenia." Acta Neuropsychiatrica 25, no. 1 (2013): 2–11. http://dx.doi.org/10.1111/j.1601-5215.2012.00638.x.

Повний текст джерела
Анотація:
ObjectivesDespite clozapine's superior clinical efficacy in treatment-resistant schizophrenia (TRS), its adverse effects, need for periodic leukocyte monitoring, cost and variable clinical outcomes mandate a clinical need to predict its treatment response. Although cytochrome P450 1A2 (CYP1A2) is the principal determinant of metabolism of clozapine, the role ofCYP1A2gene in the clinical response to clozapine is uncertain. Hence, we investigated its association with treatment responses and adverse events of clozapine in TRS.MethodsWe evaluated four single nucleotide polymorphisms (SNP) in theCY
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Lieberman, Jeffrey A., Bruce L. Saltz, Celeste A. Johns, Simcha Pollack, Michael Borenstein, and John Kane. "The Effects of Clozapine on Tardive Dyskinesia." British Journal of Psychiatry 158, no. 4 (1991): 503–10. http://dx.doi.org/10.1192/bjp.158.4.503.

Повний текст джерела
Анотація:
This article reviews eight published studies that describe clozapine's effects on TD and examines the outcome of 30 patients with TD treated with clozapine for up to 36 months. These data indicate that TD response to clozapine is variable but that approximately 43% of cases, particularly those with dystonic features, improved after clozapine treatment. Methodological limitations of the studies described, however, preclude definitive conclusions, which must await appropriately controlled trials.
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Coward, D. M. "General Pharmacology of Clozapine." British Journal of Psychiatry 160, S17 (1992): 5–11. http://dx.doi.org/10.1192/s0007125000296840.

Повний текст джерела
Анотація:
Clozapine shows neuroleptic-like inhibition of locomotor activity and conditioned avoidance responding in rodents, although tolerance develops on repeated treatment. EEG-based studies show strong arousal-inhibiting activity of clozapine as well as neuroleptic-like effects on both caudate spindle duration and rat sleep-waking patterns. Effects such as apomorphine blockade, catalepsy and strong increases of plasma prolactin levels are not seen, however, and chronic treatment does not lead to dopamine D2 receptor supersensitivity. Binding studies show clozapine's highest affinities to be for dopa
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Oliveira-Souza, Ricardo de, Rogério Paysano Marrocos, and Jorge Moll. "Clozapine for severe ("kraepelinian") schizophrenia: Sustained improvement over 5 years." Dementia & Neuropsychologia 2, no. 1 (2008): 71–75. http://dx.doi.org/10.1590/s1980-57642009dn20100014.

Повний текст джерела
Анотація:
Abstract Clozapine has become a keystone in the treatment of schizophrenia because of its efficacy as an antipsychotic with negligible neuroleptic effects. The long-term stability of its effects, however, is poorly understood, because most studies have probed the usefulness of clozapine over a period of weeks to several months at the most. Knowing whether clozapine's benefits are sustained over the very long-term, i.e., more than 5 years, may be critical for cost-benefit analyses. Objective: To report the results of an open study on the efficacy of clozapine over the very long-term. Methods: T
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Dell’Osso, Liliana, Chiara Bonelli, Benedetta Nardi, et al. "Rethinking Clozapine: Lights and Shadows of a Revolutionary Drug." Brain Sciences 14, no. 1 (2024): 103. http://dx.doi.org/10.3390/brainsci14010103.

Повний текст джерела
Анотація:
The current literature globally highlights the efficacy of Clozapine in several psychiatric disorders all over the world, with an FDA indication for reducing the risk of repeated suicidal behavior in patients with schizophrenia or schizoaffective disorder. A growing field of research is also stressing a possible broader beneficial effect of Clozapine in promoting neuroprotection and neurotrophism. However, this drug is linked to several life-threatening side effects, such as agranulocytosis, myocarditis and seizures, that limit its use in daily clinical practice. For this work, a search was pe
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Orejas, O., C. Masferrer Herrera, C. Macías Castellví, and P. Flores Martínez. "Subacute psychiatric hospitalization unit: The role of clozapine." European Psychiatry 33, S1 (2016): S548—S549. http://dx.doi.org/10.1016/j.eurpsy.2016.01.2026.

Повний текст джерела
Анотація:
IntroductionSeveral studies report that Clozapine is more effective in reducing symptoms of schizophrenia, producing clinically meaningful improvements and postponing relapse than other antipsychotic strategies.ObjectivesTo analyze the prescription of Clozapine in a sample of 88 inpatients admitted to a subacute psychiatric hospitalization unit.MethodsThis is a transversal study. All patients admitted for a medium-term psychiatric treatment since 01/06/2014 to 30/11/2015 were included. Data about socio-demographical status and clinical situation were obtained and compiled in a database. This s
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Stanton, Robert J., Chris Paxos, Werner J. Geldenhuys, et al. "Clozapine underutilization in treatment-resistant schizophrenia." Mental Health Clinician 5, no. 2 (2015): 63–67. http://dx.doi.org/10.9740/mhc.2015.03.063.

Повний текст джерела
Анотація:
Abstract It has been shown that up to one third of patients with schizophrenia do not respond to antipsychotic therapy. Thus, treatment-resistant schizophrenia (TRS) remains a major mental health care challenge. Clozapine has been shown to provide superior therapeutic benefits and is approved as first-line therapy for TRS. These benefits include improvement in both positive and negative symptoms, and reduction of suicidal behavior in patients with schizophrenia. Clozapine, however, remains significantly underused for TRS. A major reason for clozapine's underuse is its substantial adverse effec
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Fehsel, K., K. Schwanke, BA Kappel, et al. "Activation of the aryl hydrocarbon receptor by clozapine induces preadipocyte differentiation and contributes to endothelial dysfunction." Journal of Psychopharmacology 36, no. 2 (2022): 191–201. http://dx.doi.org/10.1177/02698811211055811.

Повний текст джерела
Анотація:
Background: The superior therapeutic benefit of clozapine is often associated with metabolic disruptions as obesity, insulin resistance, tachycardia, higher blood pressure, and even hypertension. Aims: These adverse vascular/ metabolic events under clozapine are similar to those caused by polycyclic aromatic hydrocarbons (PAHs), and clozapine shows structural similarity to well-known ligands of the aryl hydrocarbon receptor (AhR). Therefore, we speculated that the side effects caused by clozapine might rely on AhR signaling. Methods: We examined clozapine-induced AhR activation by luciferase r
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Дисертації з теми "Clozapine"

1

Fisher, Michael. "Clozapine-induced paroxysmal discharges." Thesis, University of Newcastle upon Tyne, 2013. http://hdl.handle.net/10443/2190.

Повний текст джерела
Анотація:
The atypical antipsychotic clozapine is a widely prescribed and effective treatment for the positive and negative symptoms of schizophrenia, but reports of side effects are common. In one study EEG abnormalities were observed in 53% of patients treated with clozapine, and the absence or presence of EEG abnormalities correlated with the plasma clozapine concentration. Here, epileptiform activity was present in conventional EEG recordings from a 32 year old male patient with psychiatric illness taking clozapine for 3 weeks. Brief (ca.100ms), transient epileptiform spikes occurred at a frequency
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Mourlot-Chabanon, Pascale. "Bilan d'utilisation de la clozapine." Montpellier 1, 1997. http://www.theses.fr/1997MON11031.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

DAHER, OSCAR. "Tolerance a la clozapine (leponex*)." Saint-Etienne, 1993. http://www.theses.fr/1993STET6205.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Durão, Ana Maria Sertori. ""Grupo de acompanhamento de pacientes e familiares de portadores de esquizofrenia medicados com clozapina: o impacto sobre o cotidiano de suas vidas"." Universidade de São Paulo, 2004. http://www.teses.usp.br/teses/disponiveis/22/22131/tde-08092004-165526/.

Повний текст джерела
Анотація:
Trata-se de uma pesquisa de avaliação, de natureza qualitativa,do tipo descritivo exploratório. Que teve como proposta descrever o cotidiano do portador de esquizofrenia em três momentos: antes do uso da clozapina; após o uso da clozapina; após o uso da mesma e o acompanhamento em grupo. A população foi constituída por todos os portadores de esquizofrenia que participaram do grupo de medicações atípicas (GRUMA) em uso de clozapina e um familiar que os acompanhavam com maior freqüência ao grupo. Para coleta dos dados foram realizadas entrevistas semi-estruturadas, com pacientes e familiares, gu
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Wilkes, Susanna Jane Lawson. "An investigation into clozapine induced agranulocytosis." Thesis, University College London (University of London), 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.336629.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Tschen, Alice C. "The in vitro metabolism of clozapine, implications for an in vitro predictive test for clozapine-induced agranulocytosis." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1997. http://www.collectionscanada.ca/obj/s4/f2/dsk2/ftp03/MQ28678.pdf.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Hsu, Pei-Chun (Lisa). "Capillary electrophoresis improving clinical measurement of clozapine." Thesis, University of Canterbury. School of Biological Sciences, 2008. http://hdl.handle.net/10092/2260.

Повний текст джерела
Анотація:
Schizophrenia is a mental disorder affecting approximately one percent of the population worldwide. The introduction of the second generation antipsychotic drug, atypical antipsychotic, clozapine, has demonstrated 80% reduction in suicide incident. This drug showed effectiveness in the treatment of resistant schizophrenia, however, high concentrations of clozapine and N-desmethylclozapine in plasma exhibit the development of agranulocytosis, a possible lethal blood disorder. Therefore, constant therapeutic drug monitoring is important for patients who receive clozapine. High performance liquid
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Salmi, Peter. "Clozapine as a dopamine D1 receptor agonist /." Stockolm : Universitet Stockholms, 1998. http://catalogue.bnf.fr/ark:/12148/cb401175060.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Raaska, Kari. "Pharmacokinetic interactions of clozapine in hospitalized patients." Helsinki : University of Helsinki, 2003. http://ethesis.helsinki.fi/julkaisut/laa/kliin/vk/raaska/.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Jolivel, Céline. "Etude médico-économique de la clozapine (Leponex (R)), neuroleptique atypique, dans le traitement des schizophrénies résistantes." Bordeaux 2, 1997. http://www.theses.fr/1997BOR2P054.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Книги з теми "Clozapine"

1

author, Taylor David, ed. Clozapine handbook. Lloyd-Reinhold Communications, 2013.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

1941-, Jones Barry, Lapierre Yvon D, Canadian Psychiatric Association Meeting, Royal Society of Medicine Services (Great Britain), and Sandoz Canada, eds. Clozapine in treatment-resistant schizophrenia: A scientific update. Royal Society of Medicine Services, 1992.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Y, Meltzer Herbert, ed. Clozapine: A 5-year perspective and clinical recommendations. Physicians Postgraduate Press, 1996.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Glennie, Judith. Pharmacoeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia. Canadian Coordinating Office for Health Technology Assessment, 1997.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Lundberg, Tommie. Clozapine - an atypical neoroleptic: A pharmacokinetic, PET and clinical study. Uppsala University, 1995.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Masellis, Mario. Pharmacogenetic analysis of serotonin receptors and clinical response to clozapine in schizophrenia patients. National Library of Canada = Bibliothèque nationale du Canada, 1999.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Naber, D., F. Müller-Spahn, and F. G. Pajonk, eds. Clozapin. Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-642-60551-2.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

1954-, Watkins Linda R., and Maier Steven F, eds. Cytokines and pain. Birkhauser Verlag, 1999.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

United States. Congress. Senate. Committee on the Judiciary. Subcommittee on Antitrust, Monopolies, and Business Rights. Marketing of Clozaril: Improved safety or barrier to access : hearing before the Subcommittee on Antitrust, Monopolies and Business Rights of the Committee on the Judiciary, United States Senate, One Hundred Second Congress, first session, on the marketing of Clozaril, a drug for the treatment of schizophrenia, March 5, 1991. U.S. G.P.O., 1991.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Naber, Dieter, and Franz Müller-Spahn, eds. Clozapin Pharmakologie und Klinik eines atypischen Neuroleptikums. Springer Berlin Heidelberg, 1994. http://dx.doi.org/10.1007/978-3-642-93547-3.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Частини книг з теми "Clozapine"

1

Courtney, John C., and Cristy Akins. "Clozapine." In Encyclopedia of Clinical Neuropsychology. Springer New York, 2011. http://dx.doi.org/10.1007/978-0-387-79948-3_1643.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Courtney, John C., Cristy Akins, and Gonzalez Efrain. "Clozapine." In Encyclopedia of Clinical Neuropsychology. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-56782-2_1643-2.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Courtney, John C., Cristy Akins, and Efrain Antonio Gonzalez. "Clozapine." In Encyclopedia of Clinical Neuropsychology. Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-57111-9_1643.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Hoyer, Daniel, Eric P. Zorrilla, Pietro Cottone, et al. "Clozapine." In Encyclopedia of Psychopharmacology. Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-68706-1_1621.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Young, Stephanie, and Noreen Jakeman. "Clozapine." In Psychiatry: Breaking the ICE. John Wiley & Sons, Ltd, 2015. http://dx.doi.org/10.1002/9781118557211.ch37.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Freudenreich, Oliver. "Clozapine." In Psychotic Disorders. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-29450-2_17.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

McDougle, Christopher J., and Carolyn A. Doyle. "Clozapine." In Encyclopedia of Autism Spectrum Disorders. Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4419-1698-3_822.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

de Groot, Anton C. "Clozapine." In Monographs In Contact Allergy. CRC Press, 2022. http://dx.doi.org/10.1201/9781003158004-154.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

McDougle, Christopher J., and Carolyn A. Doyle. "Clozapine." In Encyclopedia of Autism Spectrum Disorders. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-319-91280-6_822.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Murthy, Sree Prathap Mohana. "Clozapine Treatment." In Get Through MRCPsych: Preparation for the CASC, Second edition, 2nd ed. CRC Press, 2022. http://dx.doi.org/10.1201/9780429073007-31.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Clozapine"

1

arias, sixto A., Jeffrey S. kwon, and Paul Cohen. "Clozapine-Induced Lymphocytic Alveolitis." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a5666.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Hua Chong, Dr Jun, and Dr Franz Eversheim. "Clozapine-induced reversible Brugada Syndrome." In Annual International Conferences on Cardiology & Cardiovascular Medicine Research. Global Science & Technology Forum (GSTF), 2014. http://dx.doi.org/10.5176/2382-5669_ccmr14.15.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Brauner, M. L., C. Geffert, R. Lukačin, H. W. Clement, and C. Fleischhaker. "Clozapine Monitoring in Serum and Saliva." In XVth Symposium of the Task Force Therapeutic Drug Monitoring of the AGNP. Georg Thieme Verlag, 2024. http://dx.doi.org/10.1055/s-0044-1779553.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

"O-008 - CLOZAPINE TREATMENT AND ACUTE RELAPSE'S PREVENTION IN DUAL DIAGNOSIS PATIENTS." In 24 CONGRESO DE LA SOCIEDAD ESPAÑOLA DE PATOLOGÍA DUAL. SEPD, 2022. http://dx.doi.org/10.17579/abstractbooksepd2022.o008.

Повний текст джерела
Анотація:
Objectives: to analyze prescription pattern of clozapine in dual diagnosis (DD) inpatients' and to find out if there was any association with acute relapses either from psychiatric symptoms or from substance use disorder. Material and Methods: a retrospective study was conducted with all patients admitted at Lisbon's Psychiatric Hospital Center for psychiatric inpatient treatment during a 4 months' period. Patients with a dual diagnosis at discharge were selected and their clinical files were screened to assess sociodemographic and clinical information. Results and conclusions: from a total of
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Romanova, Olga, Dmitry Sundukov, Arkady Golubev, and Mikhail Blagonravov. "Forensic evaluation of the rate of development of ARDS in cases of poisoning with clozapine and baclofen." In Issues of determining the severity of harm caused to human health as a result of the impact of a biological factor. Publishing Center RIOR, 2020. http://dx.doi.org/10.29039/conferencearticle_5fdcb03aabda96.57249908.

Повний текст джерела
Анотація:
Acute respiratory distress syndrome (ARDS) is a syndrome of severe respiratory failure. Its etiology is associated with the impact of various aggression factors, which can be divided into direct and indirect.
 The aim of our study was to identify and compare histomorphological changes in the lungs in clozapine (150 mg/kg) and Baclofen (85 mg/kg) administration, depending on the conditions of use of these drugs. Experiments were conducted on outbreed male rats weighing 250–290 g and 20 weeks old. The animals were divided into 5 groups: the controls, Baclofen (85 mg/kg), clozapine (150 mg/k
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Chane-Kene, A., F. Plassart, O. Chauvel, C. Lamisse, and JL Pons. "4CPS-174 A new breath for clozapine …" In 24th EAHP Congress, 27th–29th March 2019, Barcelona, Spain. British Medical Journal Publishing Group, 2019. http://dx.doi.org/10.1136/ejhpharm-2019-eahpconf.323.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Gupta, K., D. Mohan, and A. Agarwal. "Clozapine Induced Hypothermia: A Chilling Side Effect." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a4820.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

"ANTIDEPRESSANT EFFECTIVENESS OF CLOZAPINE IN DUAL PSYCHOSIS." In 8th World Congress of the World Association of Dual Disorders (WADD) and the 26th Congress of the Spanish Society of Dual Disorders SEPD. SEPD/WADD, 2024. http://dx.doi.org/10.17579/abstractbookdualdisorders-co-028.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

"CLOZAPINA Y TABAQUISMO: RIESGO DE INTOXICACIÓN FARMACOLÓGICA EN EL PACIENTE FUMADOR EN TRATAMIENTO CON CLOZAPINA AL ABANDONAR EL HÁBITO TABÁQUICO." In 23° Congreso de la Sociedad Española de Patología Dual (SEPD) 2021. SEPD, 2021. http://dx.doi.org/10.17579/sepd2021p033s.

Повний текст джерела
Анотація:
1. Objetivo principal: - Determinar si existe riesgo de intoxicación por Clozapina en pacientes que cesan el hábito tabáquico en la práctica clínica. Objetivos secundarios: - Discutir riesgo/beneficio de disminuir dosis de Clozapina y a qué ritmo, con el objetivo de prevenir una intoxicación. - Identificar factores de riesgo que puedan influir: índice de paquetes – año, dosis de clozapina, edad, sexo o patologías previas. 2. Material y métodos: Se ha realizado una revisión bibliográfica de 90 artículos y abstrac en base de datos PubMed, utilizando como palabras clave: interaction, clozapine, l
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Alex, Coldstream, Eissa Alyaa HA, Wiblin Louise, and Archibald Neil. "The palliative role of clozapine in advanced Parkinson’s disease." In ABN 2024 annual meeting abstracts. BMJ Publishing Group Ltd, 2024. http://dx.doi.org/10.1136/jnnp-2024-abn.102.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "Clozapine"

1

Merino, Diane, Arnaud Fernandez, Alexandre Gérard, et al. Protocol: Adverse Drug Reactions of Olanzapine, Clozapine and Loxapine in Children and Youth: A Systematic Pharmacogenetic Review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.5.0025.

Повний текст джерела
Анотація:
Review question / Objective: In children and youth treated with olanzapine, clozapine, or loxapine and having undergone genotyping, which are the pharmacogenetic variants underlying the antipsychotics' adverse drug reactions and efficacy? What are the most frequently investigated adverse drug reactions and variants ? What is described about the specific effect of CYP1A2 variants ? Therefore, we aimed to review the pharmacogenetic variants underlying olanzapine, clozapine and loxapine ADRs and/or efficacy, in children and youth having undergone genotyping. Then, assessed the most frequently inv
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Metformin shows early promise for controlling clozapine-related weight gain. National Institute for Health Research, 2016. http://dx.doi.org/10.3310/signal-000293.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Uncertain benefit of adding amisulpiride to clozapine for treatment-resistant schizophrenia. National Institute for Health Research, 2017. http://dx.doi.org/10.3310/signal-000504.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!